Shurin, M.D. Such difficulties can tremendously influence a patient’s quality of life, and we need to address these problems as part of an overall approach to effectively controlling sickle cell disease. Researchers tested cognitive functioning of 149 adult sickle cell disease patients and compared them to 47 healthy study individuals of similar age and education amounts from the same communities. All of the participants were African-American. Even more sickle cell disease patients scored lower on steps such as intellectual ability, short-term memory space, processing acceleration, and attention, than individuals in the healthful group. The sickle cell disease participants didn’t have a history of end-organ failure, stroke, high blood pressure, or other circumstances that might otherwise affect human brain function.We did not collect comprehensive data to study the coagulation or inflammatory responses during infusion of the study drugs, although such data exist from earlier trials.1,3,12,13,17,26 The between-group difference in proteins C activity in our trial was similar compared to that observed in the PROWESS study,27,28 which finding combined with expected increase in non-serious bleeding events in the DrotAA group5,13 indicates that the patients received the intended treatment; both are indirect markers of the biologic activity of DrotAA. Mortality in the placebo group was low, as compared with historical data,1,29-31 but in keeping with that observed in newer observational studies32,33 and trials.34,35 Our findings are consistent with results of the Administration of Drotrecogin Alfa in Early Stage Severe Sepsis and the Quality of Organ Failure in Pediatric Sufferers with Severe Sepsis trials, which showed that DrotAA did not reduce mortality in children or adults with severe sepsis who had a low risk of death.3,4 Our results are consistent with the selecting in the ADDRESS trial for the reason that DrotAA had not been effective in patients with an elevated disease severity.4 We can not describe the inconsistency between our findings and the reduction in mortality at 28 days that was observed in the PROWESS research.1 Our results of similar mortality at 90 days are in keeping with those of the PROWESS study at 3 months, of which time mortality was not reduced by DrotAA.36 Our research showed that DrotAA was not beneficial when administered to a inhabitants of patients for which it had been an approved treatment.